Payment overview · 2025
General Payments
$50.14
2 reported records · 2 companies
Healthcare provider profile · identity verified
Srinivas Sanka, DO
Allopathic & Osteopathic Physicians|Family Medicine · CRYSTAL RIVER, FL · NPI 1205809217
Verified facts
What the public records show
CMS Open Payments records show Srinivas Sanka, DO received $50.14 in general payments during 2025 across 2 reported records.
BridgeBio Pharma, Inc. accounted for 60.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $30.48 | 60.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.66 | 39.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $50.14 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $30.48 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
95 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 626 | 213 |
| Levothyroxine Sodium | Levothyroxine Sodium | 532 | 167 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 532 | 185 |
| Lisinopril | Lisinopril | 484 | 161 |
| Amlodipine Besylate | Amlodipine Besylate | 430 | 151 |
| Losartan Potassium | Losartan Potassium | 383 | 122 |
| Metformin Hcl | Metformin Hcl | 366 | 137 |
| Gabapentin | Gabapentin | 360 | 146 |
| Omeprazole | Omeprazole | 357 | 113 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 335 | 130 |
| Tamsulosin Hcl | Tamsulosin Hcl | 275 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 231 | 78 |
| Metoprolol Tartrate | Metoprolol Tartrate | 223 | 77 |
| Simvastatin | Simvastatin | 217 | 68 |
| Furosemide | Furosemide | 200 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 194 | 87 |
| Montelukast Sodium | Montelukast Sodium | 190 | 55 |
| Clopidogrel | Clopidogrel Bisulfate | 180 | 60 |
| Meloxicam | Meloxicam | 178 | 69 |
| Trazodone Hcl | Trazodone Hcl | 166 | 60 |
| Glipizide | Glipizide | 146 | 52 |
| Celecoxib | Celecoxib | 139 | 67 |
| Alendronate Sodium | Alendronate Sodium | 132 | 45 |
| Methylprednisolone | Methylprednisolone | 131 | 108 |
| Pravastatin Sodium | Pravastatin Sodium | 130 | 36 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 128 | 31 |
| Carvedilol | Carvedilol | 123 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 122 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 119 | 48 |
| Potassium Chloride | Potassium Chloride | 117 | 45 |
| Sertraline Hcl | Sertraline Hcl | 115 | 45 |
| Tizanidine Hcl | Tizanidine Hcl | 113 | 37 |
| Azithromycin | Azithromycin | 110 | 88 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 42 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 104 | 30 |
| Famotidine | Famotidine | 99 | 32 |
| Eliquis | Apixaban | 95 | 36 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 92 | 40 |
| Allopurinol | Allopurinol | 91 | 28 |
| Alprazolam | Alprazolam | 89 | 35 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 89 | 23 |
| Atenolol | Atenolol | 88 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 86 | 36 |
| Spironolactone | Spironolactone | 83 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 81 | 26 |
| Ezetimibe | Ezetimibe | 81 | 26 |
| Finasteride | Finasteride | 77 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 22 |
| Clonidine Hcl | Clonidine Hcl | 68 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 66 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 66 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 25 |
| Tramadol Hcl | Tramadol Hcl | 64 | 27 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 63 | 20 |
| Levetiracetam | Levetiracetam | 60 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 57 | 48 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 21 |
| Enalapril Maleate | Enalapril Maleate | 56 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 55 | 24 |
| Warfarin Sodium | Warfarin Sodium | 55 | 13 |
| Buspirone Hcl | Buspirone Hcl | 52 | 12 |
| Glipizide Er | Glipizide | 51 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | 15 |
| Clonazepam | Clonazepam | 50 | 14 |
| Nitroglycerin | Nitroglycerin | 50 | 23 |
| Prednisone | Prednisone | 50 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 49 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | 12 |
| Jardiance | Empagliflozin | 48 | suppressed |
| Glimepiride | Glimepiride | 47 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 47 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 44 | 17 |
| Nifedipine Er | Nifedipine | 41 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 38 |
| Symbicort | Budesonide/Formoterol Fumarate | 40 | 16 |
| Pregabalin | Pregabalin | 39 | 15 |
| Temazepam | Temazepam | 39 | suppressed |
| Baclofen | Baclofen | 38 | 13 |
| Fenofibrate | Fenofibrate | 38 | 15 |
| Lovastatin | Lovastatin | 38 | 12 |
| Memantine Hcl | Memantine Hcl | 38 | suppressed |
| Mirtazapine | Mirtazapine | 38 | suppressed |
| Primidone | Primidone | 38 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 38 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | 16 |
| Diazepam | Diazepam | 36 | 12 |
| Donepezil Hcl | Donepezil Hcl | 36 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 35 | 11 |
| Meclizine Hcl | Meclizine Hcl | 35 | 19 |
| Breyna | Budesonide/Formoterol Fumarate | 34 | 14 |
| Bupropion Xl | Bupropion Hcl | 34 | 13 |
| Ibuprofen | Ibuprofen | 34 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 34 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | 13 |
| Propranolol Hcl | Propranolol Hcl | 33 | 14 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 32 | 15 |
| Acyclovir | Acyclovir | 31 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | 11 |
| Metformin Hcl Er | Metformin Hcl | 31 | 11 |
| Topiramate | Topiramate | 30 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 27 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 29 | 28 |
| Sildenafil Citrate | Sildenafil Citrate | 29 | 11 |
| Valsartan | Valsartan | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 27 | 13 |
| Levemir Flexpen | Insulin Detemir | 27 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 27 | 11 |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Folic Acid | Folic Acid | 25 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 25 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 24 | suppressed |
| Methotrexate | Methotrexate Sodium | 24 | suppressed |
| Ozempic | Semaglutide | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 15 |
| Levofloxacin | Levofloxacin | 22 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 21 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 14 |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | 11 |
| Fluconazole | Fluconazole | 20 | 16 |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 16 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Nystatin | Nystatin | 20 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | 12 |
| Calcitriol | Calcitriol | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 16 |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Benzonatate | Benzonatate | 16 | 11 |
| Digoxin | Digoxin | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $50.14 · 2 records | BridgeBio Pharma, Inc. | ABRYSVO, Attruby, COMIRNATY, PREVNAR 20 | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error